Ontology highlight
ABSTRACT:
INSTRUMENT(S): LTQ Orbitrap Velos
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Blood Plasma
DISEASE(S): Glioblastoma
SUBMITTER: Frode Selheim
LAB HEAD: Martha Chekenya
PROVIDER: PXD007193 | Pride | 2019-08-20
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
10_C6A1ny.raw | Raw | |||
11_C7A2.raw | Raw | |||
12A_C7A3.raw | Raw | |||
12b_C6A5.raw | Raw | |||
13_C10A1.raw | Raw |
Items per page: 5 1 - 5 of 26 |
Rahman Mohummad Aminur MA Gras Navarro Andrea A Brekke Jorunn J Engelsen Agnete A Bindesbøll Christian C Sarowar Shahin S Bahador Marzieh M Bifulco Ersilia E Goplen Dorota D Waha Andreas A Lie Stein Atle SA Gjertsen Bjørn Tore BT Selheim Frode F Enger Per Øyvind PØ Simonsen Anne A Chekenya Martha M
British journal of cancer 20190815 7
<h4>Background</h4>Resistance to temozolomide (TMZ) is due in part to enhanced DNA repair mediated by high expression of O<sup>6</sup>-methyl guanine DNA methyltransferase (MGMT) that is often characterised by unmethylated promoter. Here, we investigated pre-treatment of glioblastoma (GBM) cells with the 26S-proteasome inhibitor bortezomib (BTZ) as a strategy to interfere with MGMT expression and thus sensitise them to TMZ.<h4>Methods</h4>Cell lines and patient GBM-derived cells were examined in ...[more]